Consorta

Consorta Pharmaceuticals is a biotechnology company focused on the development of live biotherapeutic products (LBPs) for the treatment of autoimmune and inflammatory diseases. The company's platform identifies and assembles defined consortia of human-derived bacteria that work synergistically to modulate the immune system, specifically by inducing the production of regulatory T cells (Tregs). Their current research pipeline targets conditions such as inflammatory bowel disease (IBD) and graft-versus-host disease (GvHD), as well as applications in immuno-oncology to improve response rates to existing therapies. Consorta aims to provide standardized, pharmaceutical-grade microbial therapies as an alternative to traditional immunosuppressants.